REG - Hikma Pharmaceutical - Hikma Injectables Portugal site visit

Hikma PharmaceuticalsAnnouncement

30/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221130:nRSd9929Ha&default-theme=true

RNS Number : 9929H  Hikma Pharmaceuticals Plc  30 November 2022

Hikma Injectables Portugal site visit

 

London, 30 November 2022 - Hikma Pharmaceuticals PLC (Hikma), the
multinational pharmaceutical group, is today hosting sell side analysts at its
Injectables manufacturing facility in Sintra, Portugal.

 

The visit will primarily provide the opportunity for attendees to tour this
state-of-the-art facility which serves as a global hub for the Injectables
business, the largest of Hikma's three divisions. Senior members of the
Injectables team will also present on the unique fundamentals of the business,
which has a solid track record of revenue growth and strong margins. No new
material information will be provided.

 

The presentation is available on Hikma's website at
www.hikma.com/investors/results-reports-and-presentations
(http://www.hikma.com/investors/results-reports-and-presentations) .

 

 

 

--  ENDS -

 

 

Enquiries:

Hikma
(Investors)

 Susan Ringdal                                                                                  +44 (0)20 7399 2760/ +44 7776 477050

 EVP, Strategic Planning and Global Affairs
 Guy Featherstone                                                                               +44 (0)20 3892 4389/ +44 7795 896738

 Associate Director, Investor Relations
 Layan Kalisse                                                                                  +44 (0)20 7399 2788/ +44 7970 709912

 Senior Associate, Investor Relations

 Teneo (Press)

 Charles Armitstead

                                                                                              + 44 (0) 7703 330269
 Camilla Cunningham

                                                                                                + 44 (0) 7464 982426

 

 

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)
(LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/stable Fitch)

 

Hikma helps put better health within reach every day for millions of people
around the world. For more than 40 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
the North America, the Middle East and North Africa (MENA) and Europe, and we
use our unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively and acting
practically, we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,700 colleagues are helping to shape a
healthier world that enriches all our communities. We are a leading licensing
partner, and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more information, please
visit: www.hikma.com
(https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2531421-1%26h%3D3823969217%26u%3Dhttp%253A%252F%252Fwww.hikma.com%252F%26a%3Dwww.hikma.com&data=02%7C01%7Csweiss%40Hikma.com%7C4a35048c8c764c63c86308d70efbac9e%7C178c1a723d3c40afbaa754615303bcdc%7C0%7C1%7C636994346427346162&sdata=lHZaoOb0u30Y6re6yfLW1Ar4vvBS%2FnjEUNdB00TBaTI%3D&reserved=0)

©2022 Hikma Pharmaceuticals PLC. All rights reserved.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKZMZMNLKGZZM